Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 6 SUPPL. 1, 2002, Pages

  Green, Jonathan R ^a   Clézardin, Philippe ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Apoptosis; Bisphosphonate; Osteoprotegerin; Preclinical

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CASPASE; IBANDRONIC ACID; INTEGRIN; MATRIX METALLOPROTEINASE; MEVALONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PROTEIN BCL 2; RAS PROTEIN; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE LESION; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOMODULATION; METASTASIS; MOLECULAR MECHANICS; OSTEOCLAST; OSTEOLYSIS; PRENYLATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE RESORPTION; CELL ADHESION; CELL DIVISION; DIPHOSPHONATES; DRUG SCREENING ASSAYS, ANTITUMOR; EXTRACELLULAR MATRIX; HUMANS; MODELS, ANIMAL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OSTEOCLASTS; PROTEIN ISOPRENYLATION; TUMOR CELLS, CULTURED;

EID: 0036901126     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200212001-00002     Document Type: Conference Paper

References (75)

1. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-4.
2. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220-9.
3. Derenne S, Amiot M, Barille S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999;14:2048-56.
4. Hiraga T, Williams PJ, Mundy GR, et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001;61:4418-24.
5. Lee MV, Fong EM, Singer FR, et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001;61:2602-8.
6. Mackie PS, Fisher JL, Zhou H, et al. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001;84:951-8.
7. Senaratne SG, Pirianov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-68.
8. Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity. Br J Haematol 1997;98:665-72.
9. Shipman CM, Croucher PI, Russell RG, et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998;58:5294-7.
10. Sonnemann J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-65.
11. Takahashi R, Shimazaki C, Inaba T, et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leukemia Res 2001;25:77-83.
12. Tassone P, Tagliaferri P, Galea E, et al. Growth inhibition and apoptosis are induced by zoledronic acid on human pancreatic cancer cell lines [Abstract 4736]. Proc Am Assoc Cancer Res 2002;43:956-7.
13. Adami S, Salvagno G, Guarrera G, et al. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol 1985;134:1152-4.
14. Clarke NW, Holbrook IB, McClure J, et al. Osteoclast inhibition by pamidronate in metastatic prostate cancer: A preliminary study. Br J Cancer 1991;63:420-3.
15. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992;340:1049-52.
16. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339:357-63.
17. Kanis JA, Powles T, Paterson AH, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;19:663-7.
18. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
19. Fromigué O, Body JJ. Bisphosphonates inhibit breast cancer cell proliferation and induce cell apoptosis [Abstract T036]. J Bone Miner Res 1999;14(suppl 1):S118.
20. Barille S, Akhoundi C, Collette M, et al. Metalloproteinases in multiple myeloma: Production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997;90:1649-55.
21. Jagdev SP, Croucher PI, Shipman CM, et al. Taxol and zoledronate induce apoptosis in breast cancer cells in vitro - Evidence for action via inhibition of the mevalonate pathway [Abstract B11]. Bone 2000;26(suppl):30S.
22. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001;84:1126-34.
23. Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000;14:841-4.
24. Cruz JC, Alsina M, Craig F, et al. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 2001;29:441-7.
25. Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002;116:278-90.
26. Croucher P, De Raeve H, Perry M, et al. Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma [Abstract B10]. Bone 2002;30(suppl):39S.
27. Peyruchaud O, Winding B, Pecheur I, et al. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001;16:2027-34.
28. Nobuyuki H, Hiraga T, Williams PJ, et al. The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor [Abstract F062]. J Bone Miner Res 2001;16(suppl 1):S191.
29. Alvarez E, Galbreath EJ, Westmore M, et al. Properties of bisphosphonates in the 13762 syngeneic rat mammary carcinoma model of tumor-induced bone resorption [Abstract 1571]. Proc Am Assoc Cancer Res 2002;43:316.
30. Corey E. Quinn JE, Brown LG, et al. Examination of effects of zoledronic acid on prostate cancer [Abstract F070]. J Bone Miner Res 2001;1(suppl 1):S192.
31. Green JR, Gschaidmeier H, Yoneda T, et al. Zoledronic acid potently inhibits tumour-induced osteolysis in two models of breast cancer metastasis to bone [Abstract 50P]. Ann Oncol 2000;11 (suppl 4):14.
32. Stronski SA, Bettschen-Camin L, Wetterwald A, et al. Bisphosphonates inhibit 1,25-dihydroxyvitamin D3-induced increase of osteocalcin in plasma of rats in vivo and in culture medium of rat calvaria in vitro. Calcif Tissue Int 1988;42:248-54.
33. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporosis Int 1999;9(suppl2):S66-80.
34. Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991:49:407-15.
35. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78.
36. Frith JC, Monkkonen J, Blackburn GM, et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12:1358-67.
37. Frith JC, Monkkonen J, Auriola S, et al. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001;44:2201-10.
38. Pelorgeas S, Martin JB, Satre M. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. A 31P NMR study. Biochem Pharmacol 1992;44:2157-63.
39. Rogers MJ, Russell RG, Blackburn GM, et al. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 1992;189:414-23.
40. Rogers MJ, Ji X, Russell RG, et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 1994;303(pt 1):303-11.
41. Rogers MJ, Watts DJ, Russell RGG. Overview of bisphosphonates. Cancer 1997;80(suppl):1652-60.
42. Benford HL, McGowan NW, Helfrich MH, et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001;28:465-73.
43. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
44. Selander KS, Monkkonen J, Karhukorpi EK, et al. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996;50:1127-38.
45. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-42.
46. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-51.
47. Alakangas A, Selander K, Mulari M, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002;70:40-7.
48. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000;141:4793-6.
49. Clohisy DR, O'Keefe PF, Ramnaraine ML. Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice. J Orthop Res 2001;19:554-8.
50. Van Beek ER, Lowik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002;30:64-70.
51. Viereck V, Emons G, Lauck V, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-6.
52. Gowen M, Emery JG, Kumar S. Emerging therapies for osteoporosis. Emerging Drugs 2000;5:1-43.
53. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
54. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-602.
55. Morony S, Capparelli C, Sarosi I, et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6.
56. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000;15:2211-21.
57. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002;86:1479-86.
58. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-54.
59. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890-4.
60. Magnetto S, Boissier S, Delmas PD, et al. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83:263-9.
61. van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
62. Virtanen SS, Väänänen HK, Härkönen PL, et al. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62:2708-14.
63. Teronen O, Heikkila P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann NY Acad Sci 1999;878:453-65.
64. Wood J, Bonjean K, Ruetz S, et al. Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
65. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res [In press].
66. Bonjean K, Bellahcene A, Locigno R, et al. Zoledronate modulates endothelial cell surface receptors involved in angiogenesis [Abstract 576]. Proc Am Assoc Cancer Res 2001;42:106.
67. Pécheur I, Peyruchaud O, Serre CM, et al. Integrin avb3 confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-8.
68. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-4.
69. Zimering MB. Effect of intravenous bisphosphonates on release of basic fibroblast growth factor in serum of patients with cancer-associated hypercalcemia. Life Sci 2002;70:1947-60.
70. Cuenca AG, Cheng FD, Wang HW, et al. Modulation of antigen- presenting cells (APCs) function by aminobisphosphonates enhances T-cell priming and prevents tumor-induced T-cell tolerance [Abstract 982]. Blood 2001;98:235a.
71. Pecherstorfer M, Jilch R, Sauty A, et al. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 2000;15:147-54.
72. Sansoni P, Passeri G, Fagnoni F, et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995;10:1719-25.
73. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92.
74. Das H, Wang L, Kamath A, et al. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001;98:1616-8.
75. Baker J, Verneris MR, Kivivuori SM, et al. Bisphosphonate and IPP expanded γδ? T cells have in vitro and in vivo antitumor function? [Abstract 704] Blood 2001;98:167a.